TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34002910
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) treatment
Study: 32422871
Drug: Campus forest
Normalized name: Fortesta
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Campus forest therapy program
Study: 35059248
Drug: LMET +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMET + DPP4i treatment (low-dose metformin 750 mg/day + vildagliptin 100 mg/day)
Study: 35059248
Drug: HMET treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMET treatment (high-dose metformin 1500 mg/day)
Study: 37550942
Drug: ozanimod treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ozanimod treatment
Study: 35103905
Drug: Locally produced
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally produced ready‐to‐use therapeutic food (L‐RUTF)
Study: 35183157
Drug: Balance Body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance Body Tape (BBT) treatment for 3 weeks
Study: 33256758
Drug: Single screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single screening and treatment (SST) strategy using malaria rapid diagnostic tests (RDT)
Study: 36130753
Drug: Combined low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined low energy diet (800-900 kcal/day) with meal replacement products and supervised exercise training (aerobic and resistance) three times weekly during the intensive phase (12 weeks)
Study: 32345700
Drug: Clinical pharmacist
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist intervention targeting drug-related problems (DRPs), initiated within a week of discharge, involving medical chart reviews, phone interviews, and medication reviews.
Study: 34384499
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 240, 480, 960, or 1440 mg ES16001 (SAD study)
Study: 34384499
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily doses of 480 or 960 mg ES16001 for 5 days (MAD study)
Study: 33522565
Drug: Individualized exercise
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized exercise program (2 daily sessions of 20 minutes for 5-7 days)
Study: 33392869
Drug: Subharmonic imaging
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subharmonic imaging (SHI) using Sonazoid contrast agent
Study: 32090660
Drug: Neurofeedback (NFB)
Normalized name: NFBA
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neurofeedback (NFB) treatment, 40 sessions targeting very slow cortical potential range, addressing inhibitory deficits through right and left prefrontal training.
Study: 32090660
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sham treatment).
Study: 35568668
Drug: Peri-urethral bulking
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-urethral bulking injections (PBI) with polydimethylsiloxane Urolastic (PDMS-U)
Study: 33740415
Drug: Aggressive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive hydration plus rectal NSAIDs (100 mg diclofenac or indomethacin); aggressive hydration comprised 20 mL/kg intravenous Ringer's lactate solution within 60 min from the start of ERCP, followed by 3 mL/kg per h for 8 h.
Study: 33740415
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received rectal NSAIDs (100 mg diclofenac or indomethacin) alone with normal intravenous saline (maximum of 1·5 mL/kg per h and 3 L per 24 h).
Study: 33740415
Drug: Aggressive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive hydration plus rectal NSAIDs
Study: 33740415
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rectal NSAIDs alone)
Study: 32584199
Drug: Clinical trials
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trials for therapeutics and vaccine development
Study: 32027191
Drug: Birthweight ≥1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birthweight ≥1000 g
Study: 33946255
Drug: PAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP treatment with enhanced support from a physiotherapist
Study: 34506596
Drug: Equol supplement
Normalized name: equol, (+-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equol supplement
Study: 34864830
Drug: Mindfulness mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness mobile application (Headspace) used daily for at least 6 weeks
Study: 32090464
Drug: Intraperitoneal local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal local anaesthetic (IPLA) with ropivacaine instillation followed by a 3-day infusion.
Study: 32090464
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group receiving 0.9% saline solution.
Study: 33675342
Drug: VA-fortified rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA-fortified rice (500 µg RAEs/d)
Study: 36030153
Drug: Normoglycemia checklist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycemia checklist applied preoperatively, intraoperatively, and postoperatively with continuous insulin infusion to maintain blood glucose levels between 80 to 150 mg/dl for 48 hours postoperative
Study: 35436142
Drug: Mannitol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (20 g)
Study: 34359097
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 92/22 μg
Study: 32540725
Drug: Sinacurcumin® 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinacurcumin® 80 mg daily
Study: 34235862
Drug: No TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: No TB treatment
Study: 36192209
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC): plasmapheresis/intravenous immunoglobulin
Study: 35802483
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (1.5 μg/kg)
Study: 35802483
Drug: PO acetaminophen/hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO acetaminophen/hydrocodone (0.15 mg/kg)
Study: 32488435
Drug: Advanced pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced pneumatic compression device (APCD) used once per day (instead of prescribed twice per day).
Study: 34758887
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR-NTX) induction, n = 20
Study: 34758887
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR-NTX) induction, n = 17
Study: 34787383
Drug: Direct osteopathic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct osteopathic primary care sports medicine intervention (n=18)
Study: 35039206
Drug: Topical antioxidants
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antioxidants (AOx)
Study: 33089293
Drug: Bio-Oss bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-Oss bone powder with Heal-All Oral repair membrane
Study: 32650814
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction (OHI)
Study: 32361265
Drug: Necuparanib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necuparanib (5 mg/kg subcutaneous injection once daily)
Study: 33668849
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day algal docosahexaenoic acid (DHA)
Study: 33668849
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two microencapsulated soy and corn oil tablets)
Study: 35176038
Drug: Evocalcet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evocalcet with intravenous vitamin D receptor activator (low dose < 1.5 μg)
Study: 35176038
Drug: Evocalcet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evocalcet with intravenous vitamin D receptor activator (high dose ≥ 1.5 μg)
Study: 35176038
Drug: Evocalcet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evocalcet with intravenous vitamin D receptor activator (all groups)
Study: 34721802
Drug: General Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Medicine (GM) rotation
Study: 32964624
Drug: FA‐treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA‐treatment with in-session exposure (FA‐ISE)
Study: 32964624
Drug: FA‐treatment without
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA‐treatment without in-session exposure (FA)
Study: 35728577
Drug: CAF +
Normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAF + L‐PRF
Study: 35300258
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy program (CPT)
Study: 32503657
Drug: Favipiravir 1600mg
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir 1600mg each dose, twice a day on the 1st day; 600mg each dose, twice a day from the 2nd to the 7th day, for a maximum of 14 days plus routine treatment for COVID-19.
Study: 32503657
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment for patients with COVID-19, including oxygen therapy and drugs that reduce phlegm and relieve cough.
Study: 36281496
Drug: ORMD‐0801 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORMD‐0801 8 mg BID
Study: 36281496
Drug: ORMD‐0801 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORMD‐0801 8 mg QD
Study: 36281496
Drug: ORMD‐0801 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORMD‐0801 32 mg QD
Study: 36281496
Drug: ORMD‐0801 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORMD‐0801 32 mg BID
Study: 36281496
Drug: ORMD‐0801 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORMD‐0801 16 mg QD
Study: 36281496
Drug: ORMD‐0801 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORMD‐0801 16 mg BID
Study: 36281496
Drug: ORMD‐0801 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORMD‐0801 32 mg TID
Study: 34711436
Drug: MF59-adjuvanted, cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted, cell culture-derived A/H5N1 influenza vaccine (aH5N1c), 7.5 µg hemagglutinin antigen per dose
Study: 34711436
Drug: MF59-adjuvanted, cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted, cell culture-derived A/H5N1 influenza vaccine (aH5N1c)
Study: 34635114
Drug: Carglumic acid
Normalized name: Carglumic Acid
DrugBank: Carglumic acid (DB06775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carglumic acid with standard treatment
Study: 32278779
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid treatment
Study: 36168738
Drug: NeuFlex implant
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NeuFlex implant
Study: 36168738
Drug: Integra implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integra implant
Study: 33429977
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g xylitol
Study: 33429977
Drug: 17 g
Normalized name: lancets 17 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 g xylitol
Study: 33429977
Drug: 35 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 g xylitol
Study: 33573042
Drug: Omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA supplementation (142 mg EPA, 267 mg DHA, 12 mg vitamin E, 5 µg vitamin D, six capsules twice a day for three weeks)
Study: 32271672
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously once every 3 weeks for up to 24 months
Study: 36176007
Drug: Mindfulness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation program conducted weekly for 12 weeks in addition to usual care
Study: 33758119
Drug: Substance-exposed newborn
Normalized name: Vital E- Newborn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance-exposed newborn vignette with injection heroin use
Study: 33758119
Drug: Substance-exposed newborn
Normalized name: Vital E- Newborn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance-exposed newborn vignette with prescription opioid use
Study: 34687446
Drug: Fremanezumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fremanezumab (monthly or quarterly)
Study: 38829506
Drug: Anthracycline-based neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based neoadjuvant chemotherapy
Study: 35276884
Drug: Dietary fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fibre supplementation (19.2 g/day) for 2 months
Study: 35276884
Drug: Non-responders to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders to fibre treatment
Study: 36040741
Drug: Remote care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote care (initial in-home visit followed by daily video visit facilitated by the home hospital nurse)
Study: 33257104
Drug: Anti-TT IgG
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TT IgG in oral fluid (OF)
Study: 33257104
Drug: Total IgG
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total IgG in oral fluid specimens
Study: 33257104
Drug: High oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oral fluid volume and sucking on the swab
Study: 32135138
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 μg subcutaneous injection three times daily for 26 weeks)
Study: 32135138
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous injection three times daily for 26 weeks)
Study: 33423267
Drug: CYP3A5 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CYP3A5 gene polymorphisms (specifically GG genotype and G allele of rs776746 locus)
Study: 32712674
Drug: WISCA utilization
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WISCA utilization for empiric antibiotic prescription
Study: 35012783
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 plus bevacizumab 15 mg/kg intravenously every 3 weeks for 3 cycles (bevacizumab arm)
Study: 35012783
Drug: Concurrent thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent thoracic radiotherapy (TRT) 45 Gy in 25 fractions (TRT arm)
Study: 33572825
Drug: Rice germ
Normalized name: RICE GERM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice germ supplementation (25 g twice a day for 4 weeks)
Study: 33855585
Drug: Sorafenib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib monotherapy
Study: 35767970
Drug: Jollab (saffron-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jollab (saffron-based beverage) 20 mL three times daily for 4 weeks
Study: 35767970
Drug: Placebo 20
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20 mL three times daily for 4 weeks
Study: 32921111
Drug: Attention and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention and Interpretation Therapy (AIT) for 10 weeks
Study: 32239984
Drug: Mild cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild cleanser and moisturizer used twice daily for two weeks
Study: 34262611
Drug: Sodium picosulfate,
Normalized name: sodium picosulfate, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium picosulfate, magnesium oxide, and citric acid (SPMC) oral solution bowel preparation
Study: 33530186
Drug: Standardized comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized comprehensive western medicine treatment and routine care
Study: 32621885
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH), median duration 6.2 months (IQR 2.5-12.7)
Study: 32621885
Drug: Warfarin, median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin, median duration 2.2 years (IQR 0.9-7.1)
Study: 32621885
Drug: Secondary thromboprophylaxis
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary thromboprophylaxis with warfarin
Study: 38564986
Drug: Enasidenib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enasidenib monotherapy
Study: 39075156
Drug: Sham manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham manual therapy (control)
Study: 35152531
Drug: Topical flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical flutamide plus 5% minoxidil
Study: 35236353
Drug: Intervention: Physician
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Physician office reception staff inviting patients to register on a tablet in the waiting room.
Study: 36336249
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose digital health intervention (1 session)
Study: 36336249
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose digital health intervention (12 sessions)
Study: 35449109
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation therapies (CRTs) (40 min per day, 6 days per week, for 3 weeks)
Study: 36334236
Drug: Ustekinumab 45/90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45/90 mg
Study: 33473026
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination technique (acute normovolemic hemodilution, retrograde autologous priming, integrated arterial filter oxygenator)
Study: 34801263
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with clinical T1 through T2 N+ cancer who underwent neoadjuvant therapy plus surgery
Study: 35532966
Drug: Web-based, self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based, self-administered Stop and Go Switching Task
Study: 35532966
Drug: Web-based, self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based, self-administered Figure Identification test
Study: 32054473
Drug: Targeted lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted lung denervation (TLD) combined with optimal medical therapy
Study: 33757723
Drug: Insulin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (20 U/0.5 mL administered intranasally for 2 days prior to surgery)
Study: 33757723
Drug: Control (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.5 mL saline administered intranasally for 2 days prior to surgery)
Study: 32706738
Drug: REACH text
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: REACH text message intervention (daily texts for first 6 months, option to reduce frequency for last 6 months)
Study: 32706738
Drug: REACH text
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: REACH text message intervention with monthly phone coaching for first 6 months
Study: 32706738
Drug: Participants who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who continued daily text messages for the last 6 months
Study: 36451389
Drug: Yaobitong capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yaobitong capsule
Study: 36451389
Drug: Celecoxib capsule
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib capsule
Study: 34708639
Drug: Songlingxuemaikang (SLXMK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Songlingxuemaikang (SLXMK) 500 mg per capsule, 4500 mg/d, n = 60
Study: 34708639
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium 50 mg per tablet, 50 mg/d, n = 30
Study: 32041914
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) supplementation at 600 mg every 8 hours for 3 days
Study: 35901337
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy with concurrent temozolomide and adjuvant temozolomide
Study: 34429149
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol (1 g paracetamol + 3.91 g mannitol per 100 mL), n=12
Study: 34429149
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% Saline 100 mL), n=12
Study: 35918788
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml levobupivacaine 0.25%
Study: 35918788
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml levobupivacaine 0.25%
Study: 32446311
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus Liu‐zi‐jue (a mind‐body exercise)
Study: 32006073
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment with corticosteroid injections and a controlled strength training program